App-Quantinova.ai

Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician-s choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC).

Edith A. Perez - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Capecitabine

Spanish national hereditary pancreatic cancer registry (PanFAM).

Carmen Guillen-Ponce - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Correlation of high body mass index and circulating tumor cell positivity in patients with early-stage breast cancer.

Uta Ortmann - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer.

Siqing Fu - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Erlotinib hydrochloride

SORAVE: Phase I study for the treatment of relapsed solid tumors with the combination of sorafenib and everolimus.

Lucia Nogova - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Everolimus

Development of a quantitative immunofluorescent method for analysis of nuclear and cytoplasmic p53 and p21 in circulating tumor cells (CTC) as biomarkers of response to p53-targeted therapy.

Jacky Woo - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

Bleomycin

Proof of mechanism (POM) in the first-in-human trial of two novel indenoisoquinoline, non-camptothecin topoisomerase I (TOP1) inhibitors.

James H. Doroshow - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Refractory malignancies

camptothecin

Pharmacodynamic monitoring of DNA damage biomarkers in circulating tumor cells (CTCs) to assess the mechanism of action of the topoisomerase-1 (Topo1) inhibitor, NKTR-102.

Sujita Sukumaran - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

etirinotecan pegol

Phase Ib study of CNTO 888 (anti-CCL 2) in combination with chemotherapies for treatment of patients with solid tumors.

Antonio Calles - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Carboplatin

Feasibility to obtain a chemogram in circulating tumorigenic cells to guide further treatments in refractory solid tumors.

Antonio Cubillo - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Expression of eIF4E relevant biomarkers detected in circulating tumor cells from metastatic NSCLC and prostate cancer patients using antibody-independent ApoStream technology.

Weiguo Wu - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

U.S. patients receiving resin 90Y microspheres for unresectable colorectal liver metastases: A multicenter study of 506 patients.

Andrew S. Kennedy - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal liver metastases

N/A

Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) with pharmacokinetic (PK) and biomarker correlates.

Robin Katie Kelley - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Temsirolimus

Sorafenib (S) for hepatocellular carcinoma (HCC) treatment: Russian experience in cirrhotic (C) and non-cirrhotic (non-C) patients.

Valeriy Vladimirovich Breder - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

Circulating tumor cells as prognostic and predictive markers in neuroendocrine tumors.

Mohid Shakil Khan - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

N/A

A pilot study of evaluation of a phosphorylation signature from pancreatic cancer tumors.

Andrea Wang-Gillam - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).

Matthew Raymond Smith - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

Cabozantinib

A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC).

Kim N. Chi - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Prednisone

Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.

Daniel J. George - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Ketoconazole

Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).

Diletta Bianchini - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Filters

1671 Abstracts